Frank Ruschitzka
Ruschitzka, Frank
Ruschitzka, Frank T.
Ruschitzka, Frank 1962-
VIAF ID: 2867149368793185980008 (Personal)
Permalink: http://viaf.org/viaf/2867149368793185980008
Preferred Forms
- 100 0 _ ‡a Frank Ruschitzka
-
- 100 1 _ ‡a Ruschitzka, Frank
-
- 100 1 _ ‡a Ruschitzka, Frank
-
- 100 1 _ ‡a Ruschitzka, Frank ‡d 1962-
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
Antagoniści receptorów endotelinowych w nadciśnieniu tętniczym : dalsze wskazania? | |
Combined device therapy for advanced heart failure : dissertation | |
Current approach to heart failure, 2016: | |
Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial. | |
Interleukin-1β Mediates Arterial Thrombus Formation via NET-Associated Tissue Factor | |
International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. | |
Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome: Insights From the International Takotsubo Registry | |
Is the panic about beta-blockers in perioperative care justified? | |
Is there a link between angiotensin receptor blockers and cancer? | |
Isolated right ventricular ballooning syndrome: a new variant of transient cardiomyopathy | |
Left Main Artery Thrombus Complicating Heart Transplantation in a Patient With Heparin-Induced Thrombocytopenia | |
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial | |
Long-term performance of modern coronary sinus leads in cardiac resynchronization therapy. | |
Loss of angiomiR-126 and 130a in angiogenic early outgrowth cells from patients with chronic heart failure: role for impaired in vivo neovascularization and cardiac repair capacity | |
Lyme carditis: restitutio ad integrum documented by cardiac magnetic resonance imaging | |
Mental stress induces prolonged endothelial dysfunction via endothelin-A receptors | |
Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy. | |
Mitral interventions in heart failure: time to deliver on the promise. | |
New devices in heart failure: an European Heart Rhythm Association report: developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association | |
Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension | |
Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome | |
Pericardial effusion unrelated to surgery is a predictor of mortality in heart transplant patients. | |
Positive emotions and Takotsubo syndrome: 'happy heart' or 'Diagoras' syndrome? | |
Prediction of short- and long-term mortality in takotsubo syndrome: the InterTAK Prognostic Score | |
Prognostic value of long-term blood pressure changes in patients with chronic heart failure | |
Prognostic value of mean pulmonary artery pressure in the stable phase after heart transplantation | |
Psoriasis and atherosclerosis: two plaques, one syndrome? | |
Pulmonary vein isolation using ablation index vs. CLOSE protocol with a surround flow ablation catheter | |
Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). | |
Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency | |
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis | |
Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure | |
Recurrent Clotting of a Continuous-Flow Right Ventricular Assist Device—Repeated Thrombolysis With Two Different Protocols | |
Reply: Impact of Cardio-Renal Syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up | |
Response to Letter Regarding Article, “Acetaminophen Increases Blood Pressure in Patients With Coronary Artery Disease” | |
Response to letters regarding article, “statins and the risk of cancer after heart transplantation”. | |
Retinal microvascular dysfunction in patients with coronary artery disease with and without heart failure: a continuum? | |
Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis | |
SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration. | |
Selective COX-2 inhibition improves endothelial function in coronary artery disease | |
Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension | |
Shear stress-dependent platelet function after LDL cholesterol apheresis | |
Simvastatin improves endothelial function in patients with rheumatoid arthritis | |
The subcutaneous implantable cardioverter defibrillator in daily clinical practice | |
Successful support of biventricular heart failure patients by new EXCOR® Adult pumps with bileaflet valves: a prospective study | |
Survival, quality of life and impact of right heart failure in patients with acute cardiogenic shock treated with ECMO. | |
Surviving 20 years after heart transplantation: a success story | |
Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safety. | |
Takotsubo cardiomyopathy has a unique cardiac biomarker profile: NT-proBNP/myoglobin and NT-proBNP/troponin T ratios for the differential diagnosis of acute coronary syndromes and stress induced cardiomyopathy | |
Takotsubo cardiomyopathy: still much more to learn | |
Takotsubo Recurrence: Morphological Types and Triggers and Identification of Risk Factors | |
TheEuropean Heart Journaland theEuropean Journal of Heart Failure: partners in scientific publishing | |
To the heart of the matter: coxibs, smoking, and cardiovascular risk | |
Torcetrapib impairs endothelial function in hypertension | |
Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency | |
Treatment with darusentan over 21 days improved cGMP generation in patients with chronic heart failure | |
Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy | |
Treatments targeting inotropy | |
True Anemia-Red Blood Cell Volume Deficit-in Heart Failure: A Systematic Review | |
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. | |
Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry | |
Upgrading to resynchronization therapy after chronic right ventricular pacing improves left ventricular remodelling | |
Vasopeptidase inhibition: effective blood pressure control for vascular protection | |
Ventricular assist devices as bridge to heart transplantation: impact on post-transplant infections | |
The wealth of nations and the dissemination of cardiovascular research | |
Working together in cardiovascular prevention: the common mission of the European Heart Journal and the European Journal of Preventive Cardiology. | |
Wytyczne ESC dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku | |
Year in cardiology 2017 : heart failure |